Royalty Pharma Distributions payable to non-controlling interests increased by 20.0% to $87.42M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 19.7%, from $108.80M to $87.42M.
An increase indicates higher profitability in specific joint ventures or royalty pools, requiring higher payouts.
This represents the portion of earnings or cash flows owed to minority partners or non-controlling interest holders in s...
Common in firms that operate through joint ventures or consolidated partnerships with minority equity stakes.
current_liabilities_distributions_payable_to_non_control_b67fbe| Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | $75.81M | $108.80M | $98.20M | $77.22M | $72.83M | $87.42M |
| QoQ Change | — | +43.5% | -9.7% | -21.4% | -5.7% | +20.0% |
| YoY Change | — | — | — | — | -3.9% | -19.7% |